Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability

2013 ◽  
Vol 29 (10) ◽  
pp. 1223-1230 ◽  
Author(s):  
Stuart Montgomery ◽  
Birol Emir ◽  
Hannah Haswell ◽  
Rita Prieto
Keyword(s):  
Anxiety Disorders ◽  
Term Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Long Term Treatment

Fluvoxamine in the Treatment of Trichotillomania: An 8-Week, Open-Label Study

CNS Spectrums ◽  
1998 ◽  
Vol 3 (9) ◽  
pp. 64-71 ◽  
Author(s):  
Gary A. Christenson ◽  
Scott J. Crow ◽  
James E. Mitchell ◽  
Thomas B. Mackenzie ◽  
Ross D. Crosby ◽  
...  
Keyword(s):  
Treatment Response ◽  
Term Treatment ◽  
Hair Pulling ◽  
Short Term ◽  
Open Label ◽  
Short Term Treatment ◽  
Open Label Study ◽  
Label Study ◽  
Long Term Treatment

AbstractThis short-term, open-label study investigates short- and long-term effects of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine for the treatment of trichotillomania (TTM). Additionally, this study aimed to test the hypothesis that the presence of hair pulling compulsiveness is predictive of SSRI response. Nineteen subjects meeting the Diagnostic and Statistical Manual of Mental Disorders, Third Edition Revised, (DSM-III-R) criteria for TTM were treated with fluvoxamine at doses up to 300 mg/day. Random regression analysis of change across time for patients who completed the study (n=14) and those who dropped out (n=5) revealed statistically significant improvements in Physician Rating Scale, hair-pulling episodes, Trichotillomania Impairment Scale, and Trichotillomania Symptom Severity Scale, but not in estimated amount of hair pulled. In addition, the percentage of patients' focused or compulsive hair-pulling symptoms was predictive of treatment response. Unfortunately, all three subjects who entered long-term treatment displayed substantial movement back toward baseline by the end of 6 months. We concluded that fluvoxamine produces moderate reductions in symptoms during the short-term treatment of TTM and that the presence of focused or compulsive hair pulling may be predictive of treatment response. However, responses may be short lived when treatment is extended.

Long-term Treatment with Lurasidone in Older Adults with Bipolar Depression: Results of a 6 Month Open-label Study

2015 ◽  
Vol 30 ◽  
pp. 1134
Author(s):  
B. Forester ◽  
M. Sajatovic ◽  
J. Tsai ◽  
H. Kroger ◽  
A. Pikalov ◽  
...  
Keyword(s):  
Older Adults ◽  
Bipolar Depression ◽  
Term Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Long Term Treatment

Cisapride in the Long-Term Treatment of Chronic Gastroparesis: A 2-Year Open-Label Study

1997 ◽  
Vol 25 (4) ◽  
pp. 182-189 ◽  
Author(s):  
BJ Kendall ◽  
ET Kendall ◽  
I Soykan ◽  
RW McCallum
Keyword(s):  
Gastric Emptying ◽  
Symptom Score ◽  
Gastrointestinal Symptoms ◽  
Symptomatic Improvement ◽  
Term Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Long Term Treatment

The effect of long-term cisapride therapy (20 mg orally three times daily for 2 years) on gastric emptying and gastrointestinal symptoms was investigated in 30 patients with severe gastroparesis (24 idiopathic, 6 diabetic). Symptoms were assessed every 2 months, using an overall symptom score based on six symptoms (anorexia, nausea, vomiting, pain, early satiety and bloating), and a 2-year mean overall symptom score was used for analysis. Gastric emptying was measured at 0, 6, 12, 18 and 24 months. Of the 24 patients who completed the study, 10 showed a significant improvement in gastric emptying ( P < 0.05) and felt improved on therapy, seven patients showing a > 20% improvement in overall symptom score compared to baseline. Results for 15 patients who underwent at least one follow-up gastric-emptying test showed only a weak correlation between individual symptom score and gastric emptying ( r = 0.40). Thus long-term cisapride therapy at the study dose produced long-term symptomatic improvement in 42% of patients with severe gastroparesis, with sustained acceleration of gastric emptying for up to 2 years.

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis

2017 ◽  
Vol 1 ◽  
pp. s95 ◽  
Author(s):  
Dee Anna Glaser ◽  
Adelaide A Hebert ◽  
Alexander Nast ◽  
William P Werschler ◽  
Stephen Shideler ◽  
...  
Keyword(s):  
Axillary Hyperhidrosis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Abstract Not AvailableDisclosure: Study supported by Dermira.

Sign in / Sign up

Export Citation Format

Share Document